AbbVie Inc (ABBV) is Summit Financial Wealth Advisors LLC’s 6th Largest Position

Summit Financial Wealth Advisors LLC boosted its stake in AbbVie Inc (NYSE:ABBV) by 26.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 82,308 shares of the company’s stock after purchasing an additional 17,183 shares during the quarter. AbbVie makes up 2.7% of Summit Financial Wealth Advisors LLC’s investment portfolio, making the stock its 6th largest position. Summit Financial Wealth Advisors LLC’s holdings in AbbVie were worth $7,314,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in ABBV. Country Club Trust Company n.a. increased its stake in AbbVie by 3.0% in the 2nd quarter. Country Club Trust Company n.a. now owns 4,568 shares of the company’s stock worth $332,000 after purchasing an additional 134 shares during the period. Koshinski Asset Management Inc. increased its stake in AbbVie by 28.2% in the 2nd quarter. Koshinski Asset Management Inc. now owns 11,770 shares of the company’s stock worth $853,000 after purchasing an additional 2,586 shares during the period. Alta Capital Management LLC increased its stake in AbbVie by 1.5% in the 2nd quarter. Alta Capital Management LLC now owns 27,365 shares of the company’s stock worth $1,984,000 after purchasing an additional 411 shares during the period. Atria Investments LLC grew its position in shares of AbbVie by 0.3% in the 2nd quarter. Atria Investments LLC now owns 85,167 shares of the company’s stock worth $6,175,000 after buying an additional 292 shares during the last quarter. Finally, Iberiabank Corp grew its position in shares of AbbVie by 1.2% in the 2nd quarter. Iberiabank Corp now owns 81,633 shares of the company’s stock worth $5,919,000 after buying an additional 934 shares during the last quarter. 69.54% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AbbVie Inc (ABBV) traded up $2.82 during trading on Friday, reaching $111.30. The company had a trading volume of 8,845,503 shares, compared to its average volume of 7,190,000. AbbVie Inc has a 52 week low of $60.15 and a 52 week high of $125.86. The company has a market capitalization of $177,420.00, a price-to-earnings ratio of 27.01, a PEG ratio of 1.06 and a beta of 1.61. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.44 by $0.04. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The business had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. During the same period in the prior year, the business posted $1.20 earnings per share. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. sell-side analysts predict that AbbVie Inc will post 7.46 earnings per share for the current year.

A number of equities research analysts have recently weighed in on the company. ValuEngine upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Leerink Swann set a $106.00 price objective on AbbVie and gave the company a “buy” rating in a research note on Tuesday, December 5th. Credit Suisse Group set a $135.00 price target on AbbVie and gave the stock a “hold” rating in a research note on Monday, January 29th. Zacks Investment Research cut AbbVie from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, BMO Capital Markets set a $66.00 price target on AbbVie and gave the stock a “hold” rating in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie currently has an average rating of “Buy” and a consensus price target of $117.26.

In related news, SVP Timothy J. Richmond sold 87,040 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $98.45, for a total value of $8,569,088.00. Following the transaction, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Laura J. Schumacher sold 145,510 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $96.71, for a total value of $14,072,272.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 450,743 shares of company stock worth $43,153,684. Company insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “AbbVie Inc (ABBV) is Summit Financial Wealth Advisors LLC’s 6th Largest Position” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/02/12/abbvie-inc-abbv-shares-bought-by-summit-financial-wealth-advisors-llc.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply